We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05532163
Recruitment Status : Not yet recruiting
First Posted : September 8, 2022
Last Update Posted : September 8, 2022
Sponsor:
Information provided by (Responsible Party):
Biogen

Brief Summary:
The primary objective of this study is to evaluate the radiological efficacy of SC natalizumab over time through Week 24 in natalizumab-naïve participants, as measured by brain magnetic resonance imaging (MRI). The secondary objectives of this study are to evaluate additional lesion-related radiological efficacy measures over time, relapse-based clinical efficacy measures, disability improvement and worsening (EDSS), pharmacokinetic and pharmacodynamic parameters, the immunogenicity of repeated doses, and safety in treatment-naïve participants of SC natalizumab.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis, Relapsing-Remitting Drug: Natalizumab Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Interventional, Open-Label, Single-arm Phase IV Study Over 24 Weeks to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous Natalizumab in Patients With Relapsing-Remitting Multiple Sclerosis (TYS-ON)
Estimated Study Start Date : November 1, 2022
Estimated Primary Completion Date : March 30, 2024
Estimated Study Completion Date : February 28, 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Natalizumab

Arm Intervention/treatment
Experimental: Natalizumab
Participants will receive natalizumab 300 milligrams (mg) (2*150 mg), SC injection, once every 4 weeks (Q4W) up to Week 24.
Drug: Natalizumab
Administered as specified in the treatment arm
Other Names:
  • Tysabri
  • BG00002




Primary Outcome Measures :
  1. Cumulative Number of Active Lesions (CUALs) Through Week 24 [ Time Frame: Up to Week 24 ]
    Cumulative number of active lesions will be calculated as the sum of the number of gadolinium (Gd)-enhancing lesions and new or enlarging T2 hyperintense lesions that are non-enhancing on post-gadolinium T1-weighted (T1w) scans. It is also referred to as combined unique active lesions (CUALs).


Secondary Outcome Measures :
  1. Cumulative Number of CUALs Through Weeks 4, 8, and 12 [ Time Frame: Weeks 4, 8, and 12 ]
    CUALs will be calculated as the sum of the number of Gd-enhancing lesions and new or enlarging T2 hyperintense lesions that are non-enhancing on post-gadolinium T1w scans.

  2. Absolute Number of CUALs at Weeks 4, 8, 12, and 24 [ Time Frame: Weeks 4, 8, 12, and 24 ]
    CUALs will be calculated as the sum of the number of Gd-enhancing lesions and new or enlarging T2 hyperintense lesions that are non-enhancing on post-gadolinium T1w scans.

  3. Mean Change From Baseline of CUALs at Weeks 4, 8, 12, and 24 [ Time Frame: Baseline, Weeks 4, 8, 12, and 24 ]
    CUALs will be calculated as the sum of the number of Gd-enhancing lesions and new or enlarging T2 hyperintense lesions that are non-enhancing on post-gadolinium T1w scans.

  4. Cumulative Number of New Gd-Enhancing Lesions Through Weeks 4, 8, 12, and 24 [ Time Frame: Weeks 4, 8, 12, and 24 ]
    Cumulative number will be calculated as the sum of the number of Gd-enhancing lesions through Weeks 4, 8, 12, and 24.

  5. Absolute Number of New Gd-Enhancing Lesions at Weeks 4, 8, 12, and 24 [ Time Frame: Weeks 4, 8, 12, and 24 ]
  6. Absolute Number of Persisting Gd-Enhancing Lesions at Weeks 4, 8, 12, and 24 [ Time Frame: Weeks 4, 8, 12, and 24 ]
  7. Absolute Number of Any (New or Persisting) Gd-Enhancing Lesions at Weeks 4, 8, 12, and 24 [ Time Frame: Weeks 4, 8, 12, and 24 ]
  8. Change From Baseline of Any (New or Persisting) Gd-Enhancing Lesions at Weeks 4, 8, 12, and 24 [ Time Frame: Baseline, Weeks 4, 8, 12, and 24 ]
  9. Cumulative Number of New or Enlarging T2 Lesions at Weeks 4, 8, 12, and 24 [ Time Frame: Weeks 4, 8, 12, and 24 ]
    Cumulative number will be calculated as the sum of the number of new or enlarging T2 hyperintense lesions through Weeks 4, 8, 12, and 24.

  10. Absolute Number of New or Enlarging T2 Lesions at Weeks 4, 8, 12, and 24 [ Time Frame: Weeks 4, 8, 12, and 24 ]
  11. Change From Baseline of New or Enlarging T2 Lesions at Weeks 4, 8, 12, and 24 [ Time Frame: Baseline, Weeks 4, 8, 12, and 24 ]
  12. Annualized Relapse Rate [ Time Frame: Week 24 ]
    Multiple sclerosis (MS) relapse is defined as the onset of new or recurrent neurological symptoms lasting at least 24 hours, accompanied by new objective abnormalities on a neurological examination, and not explained solely by non-MS processes such as fever, infection, severe stress, or drug toxicity. ARR is defined as the total number of relapses divided by the total participant-time at risk of relapse.

  13. Time to First Relapse [ Time Frame: Up to Week 24 ]
    MS relapse is defined as the onset of new or recurrent neurological symptoms lasting at least 24 hours, accompanied by new objective abnormalities on a neurological examination, and not explained solely by non-MS processes such as fever, infection, severe stress, or drug toxicity. Time to first MS relapse will be calculated as the date from first study drug administration through the date of the first relapse, if applicable.

  14. Number of Participants With Expanded Disability Status Scale (EDSS) Improvement and Stable Disease and Worsening at Weeks 12, and 24 [ Time Frame: Baseline, Weeks 12, and 24 ]
    The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Stable disease is defined as +/- 0.5 change of EDSS. Worsening is > 0.5 increase of EDSS.

  15. Trough Serum Natalizumab Concentration (Ctrough) [ Time Frame: Pre dose on Baseline, Weeks 4, 8, 12, and 24 ]
  16. Trough alpha 4 (α4) Integrin Saturation [ Time Frame: Pre dose on Baseline, Weeks 4, 8, 12, and 24 ]
  17. Change From Baseline in Lymphocyte Subsets Count [ Time Frame: Baseline up to Week 24 ]
    Lymphocyte subsets include T cells, B cells and natural killer cells (cluster of differentiate 4 [CD4], CD8, CD19, and CD56).

  18. Change From Baseline in Anti-Natalizumab Antibodies [ Time Frame: Pre dose on Baseline, Weeks 12, and 24 ]
  19. Persistence of Anti-Natalizumab Antibodies [ Time Frame: Re-test after 6 weeks of first positive result (up to Week 24) ]
    Re-test will be done for antibodies after 6 weeks of first positive result.

  20. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to Week 24 ]
    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. SAE is any untoward medical occurrence that at any dose results in death, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect or is a medically important event.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Diagnosis of RRMS according to the McDonald criteria
  • Treatment-naïve in respect to natalizumab as disease modifying monotherapy for RRMS
  • No or not more than one prior MS disease-modifying therapy
  • Highly active RRMS, as defined by at least one relapse in the previous year and at least one T1 gadolinium-enhancing lesion or ≥3 new or enlarging T2 lesions
  • EDSS score ≤ 5.5 at Screening
  • Estimated glomerular filtration rate (eGFR) >30 millilitre per min (mL/min), as estimated using the Cockcroft-Gault formula.

Key Exclusion Criteria:

  • Primary- and secondary-progressive MS
  • Participants for whom MRI is contraindicated
  • History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic (including diabetes), urologic, pulmonary, neurologic (except for RRMS), dermatologic, psychiatric, renal, or other major disease that would preclude participation in a clinical study
  • History of severe allergic or anaphylactic reactions or known hypersensitivity to any antibody drug therapy.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05532163


Contacts
Layout table for location contacts
Contact: US Biogen Clinical Trial Center 866-633-4636 clinicaltrials@biogen.com
Contact: Global Biogen Clinical Trial Center clinicaltrials@biogen.com

Sponsors and Collaborators
Biogen
Layout table for additonal information
Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT05532163    
Other Study ID Numbers: DE-TYS-12072
2022-001820-14 ( EudraCT Number )
First Posted: September 8, 2022    Key Record Dates
Last Update Posted: September 8, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/
URL: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Natalizumab
Immunologic Factors
Physiological Effects of Drugs